Vor Biopharma
Clinical trials sponsored by Vor Biopharma, explained in plain language.
Develops engineered hematopoietic stem cell therapies for blood cancers.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for muscle weakness: drug trial targets myasthenia gravis Results expected May 2027 (estimated) May already have reported ↗ 🚀 Make-or-break
-
New drug telitacicept aims to tame Sjögren's in major trial
Disease control Recruiting nowThis Phase 3 study tests whether telitacicept, a biologic drug given as a shot, can reduce disease activity in adults with active primary Sjögren's disease. About 250 participants will receive either telitacicept or a placebo for 48 weeks. The main goal is to see if the drug impr…
Phase 3 • Sponsor: Vor Biopharma • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New hope for muscle weakness: drug trial targets myasthenia gravis
Disease control Recruiting nowThis study tests a drug called telitacicept in 180 adults with generalized myasthenia gravis, a condition causing muscle weakness. Participants receive either the drug or a placebo for 24 weeks to see if it improves daily activities and muscle strength. The goal is to control the…
Phase 3 • Sponsor: Vor Biopharma • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC